Raise closed, search for fresh raises on Seedstage

San Antonio, TX

Revolutionizing wound care with precise, efficient, and minimally invasive debridement solutions.

• Innovative Solution: High-density plastic tool engineered for precise and minimally painful wound debridement.
• Regulatory Backing: FDA Class I registered with utility and design patents supporting strong IP foundations.
• Market Traction: Partnerships with over 70 healthcare systems globally, including Mayo Clinic and VA.
• Clinician-Friendly: Accessible across specialties, reducing clinical time and enhancing patient outcomes.
• Strategic Positioning: Addressing a $4.54B segment within the $23.1B global wound care market.

EZ Debride, Inc. is raising funds to expand its innovative wound care solutions, specifically targeting the challenges of effective wound debridement. The company’s flagship product is designed to precisely remove harmful biofilm and necrotic tissue, addressing key barriers to wound healing. By utilizing a high-density plastic instrument engineered for controlled, uniform sharp debridement, EZ Debride, Inc. enables clinicians across specialties to achieve faster, safer, and more efficient wound care with minimal risk to healthy tissue. This technology aligns with modern healthcare needs, enhancing patient comfort while promoting better outcomes.

Positioned within the growing global wound care market, EZ Debride, Inc. leverages FDA Class I registration, utility and design patents, and broad adoption across 70+ healthcare systems, including partnerships with notable organizations such as Mayo Clinic, U.S. Department of Veterans Affairs, and the U.S. Military. The company’s focus on accessibility and precision offers a solution to longstanding challenges in wound management, supporting its goal of transforming patient care and clinician efficiency.

Company Info

EZ Debride develops an innovative tool for precise, minimally painful wound care debridement, addressing biofilm challenges and enhancing healing outcomes.

EZ Debride, Inc. addresses a critical need in wound care by tackling the challenges posed by biofilm, a harmful bacteria that impedes healing and can lead to severe complications, including pain, infection, and even limb loss. The company’s flagship device, designed by a surgeon, revolutionizes sharp debridement by providing clinicians with a precise, controlled tool for removing devitalized tissue. Unlike traditional instruments like scalpels and curettes, EZ Debride minimizes patient discomfort, reduces clinical time by 60%, and expands accessibility to wound care across specialties. Its unique structure, made from high-density plastic, ensures uniform debridement while protecting healthy tissue, laying the foundation for faster and more effective healing.

Operating in a wound care market valued at $23.1 billion, with a debridement segment of $4.54 billion, EZ Debride stands out with its disposable, easy-to-use design and strong regulatory compliance as an FDA Class I instrument. Backed by utility and design patents, the company has partnerships with over 70 major healthcare organizations, including the Mayo Clinic, Veterans Affairs, and the U.S. Military. Clinical studies demonstrate the device’s superior efficacy, achieving an 87% biofilm reduction compared to 35% with traditional methods. With a growing revenue base and industry recognition, EZ Debride is poised to redefine wound care by combining precision, efficiency, and patient comfort.